Search results
Results from the WOW.Com Content Network
Left's 2015 report on Valeant Pharmaceuticals (later known as Bausch Health) accused the company of channel stuffing [38] and using sham transactions to inflate drug sales. Left's initial report focused on an investigation launched by Senator Bernie Sanders and Representative Elijah Cummings that examined Valeant's business model of massively ...
J. Michael Pearson (born 1959) is a Canadian American [1] pharmaceutical company executive. He is the former chairman and CEO of Valeant Pharmaceuticals International [2] [3] after being ousted in the aftermath of a report on pharmaceutical pricing published by Citron Research in April 2016.
Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.) is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs , primarily for skin diseases , gastrointestinal disorders , eye health ...
Andrew Left, who has long targeted companies that he thinks are over-valued through his work at Citron Research, told investors on Monday that his new hedge fund returned 43% after fees in 2019 ...
Prominent short seller Andrew Left is pressing a judge to dismiss U.S. charges that he manipulated the market and defrauded investors with his negative reports about companies, according to a ...
A federal grand jury has indicted prominent activist short seller Andrew Left on multiple counts of securities fraud for a long-running $16 million market manipulation scheme, the U.S. Justice ...
Brent Saunders (1970) is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb.He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie.
A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029.